c12G1-DM1

**c12G1-DM1** is a novel **antibody-drug conjugate (ADC)** targeting **nectin-2**, a cell surface protein highly overexpressed in ovarian cancer. It comprises a chimeric anti-nectin-2 monoclonal antibody (c12G1) conjugated via a non-cleavable SMCC linker to **DM1 (mertansine)**, a cytotoxic maytansinoid microtubule inhibitor. c12G1 specifically binds the C2 domain of human nectin-2, resulting in efficient internalization into nectin-2-positive cancer cells. The DM1 payload induces cell cycle arrest at the G2/M phase by inhibiting microtubule assembly, promoting apoptosis in dividing cells. Preclinical studies demonstrated selective cytotoxicity against nectin-2-positive ovarian cancer cell lines and significant tumor growth inhibition in xenograft models without notable toxicity. The ADC is in preclinical development for the treatment of ovarian cancer and potentially other nectin-2-expressing malignancies[1][4].